Ad
related to: maps drug checking sites free trial registration
Search results
Results From The WOW.Com Content Network
In the early 2000s, Bluelight worked with reagent test supplier EZ-Test to promote the sale of drug checking kits.. In 2007, Bluelight partnered with the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit organization working to raise awareness and understanding of psychedelic drugs through education, clinical research, and advocacy.
The DRKS is an open access, free of charge online register for clinical trials and is available both in English and German. DRKS is part of the WHO's ICTRP. The DRKS works with two partner registries in Germany, DeReG (German Registry for Somatic Gene-Transfer Trials) and Clinical Trial Registry of the University Medical Center Freiburg. [4]
A trial record manager typically provides initial trial registration prior to the study enrolling the first participant. This also facilitates informing potential participants that the trial is no longer recruiting participants. Once all participants were recruited, the trial record may be updated to indicate that is closed to recruitment.
Now Google is lending a hand by pinpointing 3,500 of these drop-off sites on Google Maps and via Search in partnership with the DEA, HHS, CVS, Walgreens and state governments.
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
For premium support please call: 800-290-4726 more ways to reach us
MAPS works closely with government regulatory authorities worldwide such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to ensure that all of its sponsored research protocols conform to ethical and procedural guidelines for clinical drug research. Included in MAPS' research efforts are MDMA ...
Lykos Therapeutics, formerly known as the MAPS Public Benefit Corporation (MAPS PBC), is a public benefit corporation (PBC) that is developing MDMA ("ecstasy") as a potential medicine. [1] It was founded and is considerably owned by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). [ 1 ]